重组人白介素-11衍生物对治疗恶性肿瘤患者化疗后血小板减少临床探析

摘要

Objective:To investigate the effect of thrombocytopenia in patients with malignant tumor who were treated with recombinant human interleukin-11 derivatives.Methods:40 patients with malignant tumor were selected from January 2012 to January 2014.With a self control,this study divided into 2 periods,in the first treatment cycles,did not given rhIL-11 after chemotherapy,while in the second cycles,patients were given rhIL-11 within 24~48 h after chemotherapy,then we compared thrombocytopenic conditions in two groups.Results:In those 40 patients the lowest value of platelet count in the second cycle was significantly higher than that in the first period(P<0.05);the duration of platelet count less than 50 × 109/L was significantly shorter than the first cycles(P<0.05),and the time of platelet recovery to normal value also was obviously shorter than the first cycles(P<0.05);the incidence of platelet transfusion was significantly less than the first cycles(P<0.05);none of the patients occurred hemorrhage in second cycles,and the adverse reaction was mild.Conclusion:RhIL-11 derivatives used in patients with malignant tumor has significantly effect on prevention of thrombocytopenia after chemotherapy,and the adverse reactions is mild, so it is worthy of popularization and application.%目的：探讨重组人白介素-11(rhIL-11)衍生物在治疗恶性肿瘤患者化疗后血小板减少的临床应用效果。方法：2012年1月-2014年1月收治恶性肿瘤患者40例，采用自身对照试验，分为2个周期，第1个治疗周期化疗后不加用rhIL-11，第2个周期化疗后24～48 h内加用rhIL-11治疗，比较两组血小板减少情况。结果：40例患者在第2个周期时的血小板计数最低值明显高于第1个周期(P＜0.05)，血小板计数≤50×109/L的持续时间明显小于第1个周期(P＜0.05)，血小板恢复至正常值的时间明显短于第1个周期(P＜0.05)，输注血小板的发生率明显小于第1个周期(P＜0.05)，所有患者第2个周期无出血发生，且不良反应轻微。结论：rhIL-11衍生物在预防恶性肿瘤患者化疗后血小板减少中的作用显著，且不良反应轻微，值得推广应用。